 |
BioWorld-Insight-2010-06-07
Weighing the FDA's Proposal To Lift the Veil on CR Letters
ASCO and Ye Shall Receive: Data Flow Perks Wall Street
The anticipated spill-out of clinical results from the American Society of Clinical Oncology meeting in Chicago continued to, well, spill out as the first part of the week wore on, with outcomes due from various quarters in experiments against a particularly devilish form of cancer: pancreatic. Few tumor types bear a development path as casualty-strewn, other than melanoma - which also promised to yield encouraging news from ASCO. (See BioWorld Insight, May 24, 2010.)